On Thursday, H.C. Wainwright adjusted its rating for Panbella Therapeutics shares (NASDAQ:PBLA), moving it from Buy to Neutral.
The downgrade follows the biopharmaceutical company's first-quarter earnings report, which revealed a loss per share of $2.28, deviating significantly from both the analyst's expectation of a $1.23 loss and the consensus estimate of a $1.62 loss. Panbela concluded the quarter with a mere $262,000 in cash reserves.
The company's management has indicated an anticipated increase in quarterly cash burn to approximately $7 million as it ramps up enrollment in clinical trials. To sustain its operations, Panbela will need to secure additional funding.
In April 2024, the company filed an S-1 indicating plans to list on the US Equity Listings Tier II of the Chicago Board Options Exchange (CBOE). A successful listing would allow Panbela to raise further capital through an offering.
Still, a significant hurdle remains: Panbela's stock price must reach at least $4.00 per share to satisfy the initial listing requirements of the CBOE. The company is contemplating a reverse stock split to achieve this price threshold, subject to shareholder approval.
This potential move comes on the heels of previous reverse stock splits in January 2024 and June 2023, which were executed at ratios of 1:20 and 1:30, respectively.
The need for additional capital and the potential dilution of shares due to the reverse stock split and listing efforts are key factors behind the downgrade. H.C. Wainwright cites these cash and listing risks as significant detractors from the potential value of Panbela's extensive clinical trial activities, which include trials that have recently commenced or are slated to begin soon.
InvestingPro Insights
As Panbela Therapeutics navigates through its financial challenges and clinical trial advancements, insights from InvestingPro reveal critical aspects of the company's financial health and stock performance.
With a market capitalization of just $2.09 million and a concerning adjusted P/E ratio of -0.06, the company's financial position appears precarious. The stock's performance reflects these difficulties, with a staggering 99.83% decline in the one-year price total return, underscoring the steep uphill battle Panbela faces to reach the CBOE's listing requirements.
InvestingPro Tips highlight two particularly relevant concerns for investors: the company's weak gross profit margins and the fact that short-term obligations exceed liquid assets. These factors, combined with the analysts' consensus that Panbela will not be profitable this year, paint a sobering picture for the biopharmaceutical firm's immediate future.
Furthermore, the stock has experienced significant depreciation over the last three months, six months, and even the last decade, indicating long-term performance issues that prospective and current investors must consider.
For those looking to delve deeper into the financial intricacies and future prospects of Panbela Therapeutics, InvestingPro offers additional insights. There are 10 more InvestingPro Tips available that could provide a more nuanced understanding of the company's position and potential strategies for investors. To access these valuable tips and make more informed investment decisions, readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.